Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2020 16:01 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) --...
July 21, 2020 08:30 ET | Source: Arcturus Therapeutics Holdings Inc.; Duke-NUS Medical School

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing...
July 01, 2020 08:00 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical...
June 29, 2020 08:00 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to be Added to Russell 2000® Index

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
June 11, 2020 08:00 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
June 05, 2020 08:00 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
May 08, 2020 09:30 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all...
May 07, 2020 16:01 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19);New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains on track to begin...
May 04, 2020 15:00 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
May 04, 2020 08:39 ET | Source: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

SAN DIEGO and SOMERSET, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines...